Publication:
A proprietary GMP human platelet lysate for the expansion of dermal fibroblasts for clinical applications.

dc.contributor.authorFernandez Muñoz, Beatriz
dc.contributor.authorLopez-Navas, Luis
dc.contributor.authorGonzalez Bermejo, Maria
dc.contributor.authorLomas Romero, Isabel Maria
dc.contributor.authorMontiel Aguilera, Miguel Angel
dc.contributor.authorCampos Cuerva, Rafael
dc.contributor.authorArribas Arribas, Blanca
dc.contributor.authorNogueras, Sonia
dc.contributor.authorCarmona Sanchez, Gloria
dc.contributor.authorSantos Gonzalez, Monica
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderEuropean RegionalDevelopment Fund/European Social Fund “A way to make Europe”)
dc.date.accessioned2023-02-09T10:39:06Z
dc.date.available2023-02-09T10:39:06Z
dc.date.issued2020-11-19
dc.description.abstractRecent years have witnessed the introduction of ex vivo expanded dermal fibroblasts for several cell therapy and tissue-engineering applications, including the treatment of facial scars and burns, representing a promising cell type for regenerative medicine. We tested different in-house produced human platelet lysate (HPL) solutions against fetal bovine serum as supplements for in vitro fibroblast expansion by comparing cell yield, molecular marker expression, extracellular matrix (ECM) generation, genomic stability and global gene expression. Our in-house produced HPL supported fibroblast growth at levels similar to those for FBS and commercial HPL products and was superior to AB human serum. Cells grown in HPL maintained a fibroblast phenotype (VIM+, CD44+, CD13+, CD90+), ECM generation capacity (FN+, COL1+) and a normal karyotype, although gene expression profiling revealed changes related to cell metabolism, adhesion and cellular senescence. The HPL manufacturing process was validated within a GMP compliant system and the solution was stable at -80ºC and -20ºC for 2 years. Dermal fibroblasts expanded in vitro with HPL maintain a normal karyotype and expression of fibroblast markers, with only minor changes in their global gene expression profile. Our in-house produced GMP-HPL is an efficient, safe and economical cell culture supplement that can help increase the healthcare activity of blood transfusion centers through the re-use of transfusional plasma and platelets approaching their expiration date. Currently, our HPL solution is approved by the Spanish Agency of Medicines and Medical Devices and is being used in the manufacture of cell therapy products.Abbreviations: AB plasma: plasma group AB; ABHS: AB Human Serum; ABHS+GF: AB Human Serum supplemented with growth factors; ANOVA: Analysis of variance; ATMPs: Advanced Therapies for Medicinal Products; CPE: cytopathic effect; DEGs: Differentially expressed genes; DMEM: Dulbecco's modified Eagle's Medium; ECM: Extracellular matrix; ELISA: enzyme-linked immunosorbent assay; FBS: Fetal bovine serum; FDR: False discovery rate; FGF: Fibroblast growth factor; GMP: Good manufacturing practice; HPL: Human platelet lysate; HPL-CM: commercial human platelet lysate; MSCs: mesenchymal stem cells; NEAA: non-essential amino acids; P/S: penicillin/streptomycin; PBS: phosphate buffered saline; PC: leukodepleted platelet concentrate; PCR: polymerase chain reaction; PDGF: Platelet-derived growth factor; PDGFRA: Platelet-derived growth factor receptor alpha; qPCR: quantitative polymerase chain reaction; RNA: Ribonucleic acid; RT: Room temperature; TAC: Transcriptome analysis console; TGF-β: Transforming growth factor beta.
dc.description.versionSi
dc.identifier.citationFernández Muñoz B, Lopez-Navas L, Gonzalez Bermejo M, Lomas Romero IM, Montiel Aguilera MÁ, Campos Cuerva R, et al. A proprietary GMP human platelet lysate for the expansion of dermal fibroblasts for clinical applications. Platelets. 2022 Jan 2;33(1):98-109.
dc.identifier.doi10.1080/09537104.2020.1856356
dc.identifier.essn1369-1635
dc.identifier.pmid33393414
dc.identifier.unpaywallURLhttps://www.tandfonline.com/doi/pdf/10.1080/09537104.2020.1856356?needAccess=true
dc.identifier.urihttp://hdl.handle.net/10668/16904
dc.issue.number1
dc.journal.titlePlatelets
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba-IMIBIC
dc.organizationFundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla-FISEVI
dc.organizationFundación Pública Andaluz Progreso y Salud-FPS
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationC.T.S. Sevilla
dc.page.number98-109
dc.provenanceRealizada la curación de contenido 05/09/2024
dc.publisherTaylor & Francis
dc.pubmedtypeJournal Article
dc.relation.projectIDDTS17/00137
dc.relation.publisherversionhttps://www.tandfonline.com/doi/full/10.1080/09537104.2020.1856356
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCell therapy
dc.subjectDermal fibroblasts
dc.subjectGood manufacturing practice
dc.subjectHuman platelet lysate
dc.subjectRegenerative medicine
dc.subject.decsAnimales
dc.subject.decsBovinos
dc.subject.decsFeto
dc.subject.decsFibroblastos
dc.subject.decsPlaquetas
dc.subject.meshAnimals
dc.subject.meshBlood Platelets
dc.subject.meshCattle
dc.subject.meshFetus
dc.subject.meshFibroblasts
dc.subject.meshHumans
dc.titleA proprietary GMP human platelet lysate for the expansion of dermal fibroblasts for clinical applications.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number33
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Fernandez Muñoz_AProprietary.pdf
Size:
10.01 MB
Format:
Adobe Portable Document Format